Trial Profile
Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Reltecimod (Primary)
- Indications Bacterial infections; Soft tissue infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Atox Bio
- 20 Nov 2012 Results were reported in an Atox Bio media release.
- 08 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Dec 2011 Additional lead trial investigators identified as reported by ClinicalTrials.gov.